Skip to Main Content

Advertisement

Skip Nav Destination

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Blood Adv (2023) 7 (18): 5272–5280.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement